GLAXOSMITHKLINE has advised
that it has now settled a
“substantial majority of product
liability cases relating to Avandia”.
Estimated to have cost around
US$460m, the announcement
comes one day after the FDA
agreed to keep the product on the
shelves, but with stricter labelling
warnings (PD yesterday).The above article was sent to subscribers in Pharmacy Daily's issue from 16 Jul 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 16 Jul 10
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.